>Gaceta Médica de México
>Year 2015, Issue 2
Rodríguez-Violante M, Velázquez-Osuna S, Cervantes-Arriaga A, Corona-Vázquez T, de la Fuente-Sandoval C
Prevalence, associated factors and phenomenology of psychosis in patients with Parkinson’s disease (PD)
Gac Med Mex 2015; 151 (2)
PDF: 109.54 Kb.
Introduction: Psychosis associated with Parkinson’s disease is a major neuropsychiatric complication; it has been reported
that 60% of patients will develop psychosis during the disease evolution. Its pathophysiology is multifactorial and clinically
psychotic phenomena include minor hallucinations and confusional states. Material and Methods: We performed a cross-sectional
study in patients with Parkinson’s disease from a tertiary hospital using a thoughtful neurological and neuropsychiatric evaluation
along with specific scales for non-motor symptoms, depression, cognition, and presence and severity of psychotic symptoms
and hallucinations. Results: We included a total of 236 patients with Parkinson’s disease, of which 33 (13.9%) patients met
the criteria for psychosis at the time of the evaluation. Visual hallucinations were the most common symptom. Age (p = 0.004),
age at onset of the disease (p = 0.007) and its duration (p = 0.004), use of levodopa (p = 0.02), and use of amantadine
(p = 0.004) were the main factors associated with the presence of psychosis. Conclusion: Psychosis in Parkinson’s disease is a relatively common manifestation and is mainly associated with clinical and demographic factors. Early recognition will
optimize management and improve the quality of life of patients and their caregivers.
||Parkinson’s disease, Psychosis, Visual hallucination, Illusion, Prevalence, Associated factors.
Fénelon G, Alves G. Epidemiology of psychosis in Parkinson’s disease. J Neurol. 2010;289(1-2):12-7.
Forsaa EB, Larsen JP, Wentzel-Larsen T, et al. A 12-year population- based study of psychosis in Parkinson disease. Arch Neurol. 2010;67(8):996-1001.
Hely MA, Reid WG, Adena MA, Halliday GM, Morris JG. The Sydney multicenter study of Parkinson’s disease: the inevitability of dementia at 20 years. Mov Disord. 2008;23(6):837-44.
Mack J, Rabins P, Anderson K, et al. Prevalence of Psychotic Symptoms in a Community-Based Parkinson’s Disease Sample. Am J Geriatr Psychiatry. 2012;20(2):123-32.
Stella F, Banzato CEM, Quagliato EMAB, Viana MA, Christofoletti G. Psychopathological features in patients with Parkinson’s disease and related caregivers’ burden. Int J Geriatr Psychiatry. 2009;24(10):1158-65.
McKinlay A, Grace RC, Dalrymple-Alford JC, Anderson T, Fink J, Roger D. A profile of neuropsychiatric problems and their relationship to quality of life for Parkinson’s disease patients without dementia. Parkinsonism Relat Disord. 2008;14(1):37-42.
Goetz CG, Wuu J, Curgian LM, Leurgans S. Hallucinations and sleep disorders in PD: six-year prospective longitudinal study. Neurology. 2005;64(1):81-6.
Schrag A, Dodel R, Spottke A, Bornschein B, Siebert U, Quinn NP. Rate of clinical progression in Parkinson’s disease. A prospective study. Mov Disord. 2007;22(7):938-45.
Lee AH, Weintraub D. Psychosis in Parkinson’s disease without dementia: Common and comorbid with other non-motor symptoms. Mov Disord. 2012;27(7):858-63.
Yoritaka A, Shimo Y, Takanashi M, et al. Motor and non-motor symptoms of 1453 patients with Parkinson’s disease: Prevalence and risks. Parkinsonism Relat Disord. 2013;19(8):725-31.
Williams DR, Lees AJ. Visual hallucinations in the diagnosis of idiopathic Parkinson’s disease: a retrospective autopsy study. Lancet Neurol. 2005;4(10):605-10.
Zahodne LB, Fernandez HH. Pathophysiology and treatment of psychosis in Parkinson’s disease: a review. Drugs Aging. 2008;25(8):665-82.
Goldman J. An update expert opinion on management and research strategies in Parkinson’s disease psychosis. Expert Opin Pharmacotherap. 2011;12(13):2009-24.
MacDonald AA, Monchi O, Seergobin KN, Ganjavi H, Tamjeedi R, MacDonald PA. Parkinson’s disease duration determines effect of dopaminergic therapy on ventral striatum function. Mov Disord. 2013; 28(2):153-60.
Harding AJ. Clinical correlates of selective pathology in the amygdala of patients with Parkinson’s disease. Brain. 2002;125(Pt 11):2431-45.
Onofrj M, Bonanni L, Albani G, Mauro A, Bulla D, Thomas A. Visual hallucinations in Parkinson’s disease: Clues to separate origins. J Neurol Sci. 2006;248(1-2):143-50.
Diederich N, Goetz C, Stebbins G. Repeated visual hallucinations in Parkinson’s disease as disturbed external/internal perceptions: focused review and a new integrative model. Mov Disord. 2005;20(2): 130-40.
Morgante L, Colosimo C, Antonini A, et al. Psychosis associated to Parkinson’s disease in the early stages: relevance of cognitive decline and depression. J Neurol Neurosurg Psychiatry. 2012;83(1):76-82.
Zhu K, van Hilten JJ, Putter H, Marinus J. Risk factors for hallucinations in Parkinson’s disease: results from a large prospective cohort study. Mov Disord. 2013;28(6):755-62.
Ravina B, Marder K, Fernandez HH, et al. Diagnostic criteria for psychosis in Parkinson’s disease: report of an NINDS, NIMH work group. Mov Disord. 2007;22(8):1061-8.
Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson’s disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry. 1992;55(3):181-4.
Cervantes-Arriaga A, Rodríguez-Violante M, Villar-Velarde A, Corona T. Cálculo de unidades de equivalencia de levodopa en enfermedad de Parkinson. Arch Neurocien (Mex). 2009;14:116-9.
Hoehn MM, Yahr MD. Parkinsonism : onset, progression, and mortality. Neurology. 1967;17(5):427-42.
Goetz CG, Poewe W, Rascol O, et al. Movement Disorder Society Task Force report on the Hoehn and Yahr staging scale: status and recommendations. Mov Disord. 2004;19(9):1020-8.
Goetz CG, Tilley BC, Shaftman SR, et al. Movement Disorder Society- sponsored revision of the Unified Parkinson’s Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov Disord. 2008;23(15):2129-70.
Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh J. An inventory for measuring depression. Arch Gen Psychiatry. 1961;4:561-71.
Folstein MF, Robins LN, Helzer JE. The Mini-Mental State Examination. Arch Gen Psychiatry. 1983;40(7):812.
Kay SR, Opler LA, Lindenmayer JP. The Positive and Negative Syndrome Scale (PANSS): rationale and standardisation. Br J Psychiatry Suppl. 1989;(7):59-67.
Kay SR, Fiszbein A, Vital-Herne M, Fuentes LS. The Positive and Negative Syndrome Scale--Spanish adaptation. J Nerv Ment Dis. 1990;178(8):510-7.
Wada-Isoe K, Ohta K, Imamura K, et al. Assessment of hallucinations in Parkinson’s disease using a novel scale. Acta Neurol Scand. 2008;117(1):35-40.
Papapetropoulos S, Katzen H, Schrag A, et al. A questionnaire-based (UM-PDHQ) study of hallucinations in Parkinson’s disease. BMC Neurol. 2008;8:21.
Fénelon G, Soulas T, Zenasni F, Cleret de Langavant L. The changing face of Parkinson’s disease-associated psychosis: a cross-sectional study based on the new NINDS-NIMH criteria. Mov Disord. 2010;25(6):763-6.
Lee AH, Weintraub D. Psychosis in Parkinson’s disease without dementia: common and comorbid with other non-motor symptoms. Mov Disord. 2012;27(7):858-63.
Fénelon G, Mahieux F, Huon R, Ziégler M. Hallucinations in Parkinson’s disease Prevalence, phenomenology and risk factors. Brain. 2000;123(Pt 4):733-45.
Rodríguez-Violante M, Cervantes-Arriaga A, Villar-Velarde A, Corona T. Relationship between the type and side of motor symptoms with the prevalence of non-motor symptoms in Parkinson’s disease. Neurologia. 2011;26(6):319-24.
Birkmayer W, Riederer P. Responsibility of extrastriatal areas for the appearance of psychotic symptoms (clinical and biochemical human post-mortem findings). J Neural Transm. 1975;37(2):175-82.
Pollak P, Tison F, Rascol O, et al. Clozapine in drug induced psychosis in Parkinson’s disease: a randomised, placebo controlled study with open follow up. J Neurol Neurosurg Psychiatry. 2004;75(5):689-95.
The French Clozapine Study Group. Clozapine in drug - induced psychosis in Parkinson’s disease. Lancet. 1999;353(9169):2041-2.
Mohr E, Mendis T, Hildebrand K, Deyn PP. Risperidone in the treatment of dopamine-induced psychosis in Parkinson’s disease: an open pilot trial. Mov Disord. 2000;15(6):1230-7.
>Gaceta Médica de México
>Year 2015, Issue 2